The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with urological cancers: A meta-analysis

Li, Menglan; Deng, Qianyun; Zhang, Lei; He, Siying; Rong, Jialing; Zheng, Fang

doi:10.1016/j.prp.2018.10.026

Cited by 15 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are several limitations in the current study. First, several peripheral blood count-based biomarkers have been previously investigated in various cancers, before and after the advent of ICIs, such as the neutrophil-to-lymphocyte ratio [ 52 , 53 , 54 , 55 , 56 ], lymphocyte-to-monocyte ratio [ 52 , 55 , 57 ], and platelet-to-lymphocyte ratio [ 52 , 54 , 58 , 59 , 60 ]. The current study chose to investigate NER (instead of other indices) based on our clinical observation of eosinophil count elevation and the established prognostic role of neutrophilia in mRCC in the IMDC model [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Chen

Tucker

Brown

et al. 2022

Cancers

View full text Add to dashboard Cite

A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/nivolumab (ipi/nivo) initiation and treatment responses in mRCC. A retrospective study of ipi/nivo-treated mRCC at two US academic cancer centers was conducted. A landmark analysis at week 6 was performed to assess the association between the change in NER and clinical responses (progression-free survival (PFS)/overall survival (OS)). Week 6 NER was modeled as a continuous variable, after log transformation (Ln NER), and a categorical variable by percent change. There were 150 mRCC patients included: 78% had clear cell histology, and 78% were IMDC intermediate/poor risk. In multivariable regression analysis, every decrease of 1 unit of Ln NER at week 6 was associated with improved PFS (adjusted hazard ratio (AHR): 0.78, p-value:0.005) and OS (AHR: 0.67, p-value: 0.002). When NER was modeled by percent change, decreased NER > 50% was associated with improved PFS (AHR: 0.55, p-value: 0.03) and OS (AHR: 0.37, p-value: 0.02). The decrease in week 6 NER was associated with improved PFS/OS in ipi/nivo-treated mRCC. Prospective studies are warranted to validate NER change as a biomarker to predict ICI responses.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Chen

Tucker

Brown

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The immune system, including the inflammatory response and tumor microenvironment, plays an important role in clinical and biological behavior as well as the outcome of RCC [ 8 ]. Inflammation-based prognostic scores such as platelet to lymphocyte ratio [ 9 ], lymphocyte to monocyte ratio [ 10 ], and prognostic nutritional index [ 11 ] are used in cancer patients [ 12 ]. The systemic immune-inflammation index (SII) combines three immune cell counts, neutrophils, lymphocytes, and platelets, into a simple formula and comprehensively maps the cancer-related inflammatory burden [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Stühler¹,

Herrmann²,

Rausch³

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the predictive and prognostic value of the systemic immune-inflammation index (SII) in patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab. Methods: This retrospective study included forty-nine mRCC patients treated with first-line ipilimumab plus nivolumab at the Department of Urology of the University of Tuebingen, Germany. SII was assessed before starting ipilimumab plus nivolumab therapy at the time of first imaging and at tumor progression. Optimal SII cut-off was stratified by ROC-analysis. Univariable and multivariable Cox regression analyses were used to evaluate the predictive and prognostic value of SII. Results: Optimal SII cut-off was 788. Twenty-nine/forty-nine patients had high SII (≥788) before initiation of ipilimumab plus nivolumab. High SII was an independent prognostic factor for worse progression-free (HR 2.70, p = 0.014) and overall survival (HR 10.53, p = 0.025). The clinical benefit rate was higher for patients with low SII if compared to high SII (80% vs. 32.1%). An increase in SII > 20% from baseline after twelve weeks of therapy was associated with progression at first imaging (p = 0.003). Conclusions: SII is both prognostic and predictive and could refine decision making in patients with unclear imaging on therapy with ipilimumab plus nivolumab.

show abstract

“…The role of the immune system in various stages of cancer progression has been extensively investigated over the last few years ( 8 ). Inflammation-based prognostic scores such as platelet-to-lymphocyte ratio ( 9 ), lymphocyte to monocyte ratio ( 10 ), and prognostic nutritional index ( 11 ) are cost-effective and reliable prognostic tools that are widely used in patients with cancer ( 10 , 12 ). Many studies have shown that the systemic immune-inflammation index (SII) is a useful prognostic marker for several malignant tumors, including pancreatic ( 13 ), gallbladder ( 14 ), non-small-cell lung ( 15 ), and laryngeal cancer ( 16 ), as well as for cholangiocarcinoma ( 17 ).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Jin¹,

Yuan²,

Yuan

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe systemic immune-inflammation index (SII) is a hematological parameter based on neutrophil, platelet, and lymphocyte counts. Studies that have investigated the prognostic value of SII in patients with renal cell carcinoma (RCC) have reported controversial results. In this study, we systematically investigated the prognostic value of SII in patients with RCC.MethodsWe systematically searched English articles in the PubMed, Embase, Web of Science, and Cochrane Library databases up to October 2021. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were used to obtain pooled results.ResultsThe meta-analysis included 10 studies that enrolled 3,180 patients. A high SII was associated with poor overall survival (HR 1.75, 95% CI 1.33–2.30, p<0.001) in patients with RCC. However, a high SII was not shown to be a significant prognostic factor for progression-free survival/disease-free survival (HR 1.22, 95% CI 0.84–1.76, p=0.293) or poor cancer-specific survival (HR 1.46, 95% CI 0.68–3.12, p=0.332) in patients with RCC. A high SII was correlated with male sex (OR 1.51, 95% CI 1.11–2.04, p=0.008), Fuhrman grade G3–G4 (OR 1.80, 95% CI 1.08–3.00, p=0.024), and poor risk based on the International Metastatic Renal Cell Carcinoma Database Consortium criteria (OR 19.12, 95% CI 9.13–40.06, p<0.001).ConclusionA high SII was independently associated with poor survival outcomes in patients with RCC. Additionally, an elevated SII indicated more aggressive disease. The SII may serve as a useful cost-effective prognostic indicator in patients with RCC.

show abstract

The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with urological cancers: A meta-analysis

Cited by 15 publications

References 41 publications

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab

Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis

Contact Info

Product

Resources

About